FM8 1030
construction of novel risk models, which achieved better patient selection for biopsy
compared with the other prediction tools alone. The novel models predict significant
cancer and can help reduce unnecessary biopsies.
897
The Next Generation of Prostate Cancer Risk CalculatorsT. Hermanns, C. Poyet
899
Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform DecisionsS. Loeb, Q. Zhou, U. Siebert, U. Rochau, B. Jahn, N. Mühlberger, H.B. Carter, H. Lepor,
R.S. Braithwaite
Active surveillance extends life more than watchful waiting, particularly for men
with higher-risk features, but this is partly offset by decrements in quality of life
from delayed treatment. Trade-offs about the intensity of surveillance should be
discussed with patients.
908
Real-time Watchful Surveillance Looks Like Active WaitingC. Bangma, M. Roobol
910
Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival AnalysisG. Gandaglia, S.A. Boorjian, W.P. Parker, E. Zaffuto, N. Fossati, M. Bandini, P. Dell’Oglio,
N. Suardi, F. Montorsi, R.J. Karnes, A. Briganti
Prognosis of patients with prostate-specific antigen (PSA) persistence varies
according to pathologic characteristics. Increasing PSA levels at 6–8 wk are
associated with a worse prognosis, exclusively in individuals with a higher risk
of cancer-specific mortality (CSM) according to their pathologic characteristics.
Postoperative radiotherapy could provide a benefit in terms of survival, particularly
in men with a risk of CSM of >20%.
918
Balancing Risks in Prostate-specific Antigen Recurrence: The Fox Versus the HedgehogB.F. Koontz
920
Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based StudyF.B. Thomsen, F. Sandin, H. Garmo, I.F. Lissbrant, G. Ahlgren, M. Van Hemelrijck, J. Adolfsson,
D. Robinson, P. Stattin
We found no difference in the risk of cardiovascular disease or death between
gonadotrpin-releasing hormone agonists and orchiectomy as treatments
for prostate cancer. Accordingly, no evidence was found in favour of changing
the standard hormonal treatment for prostate cancer.
929
Type of Androgen Deprivation Therapy and Risk of Cardiovascular DiseaseN.L. Keating
931
Recreational Physical Activity in Relation to Prostate Cancer–specific Mortality Among Men with Nonmetastatic Prostate CancerY. Wang, E.J. Jacobs, S.M. Gapstur, M.L. Maliniak, T. Gansler, M.L. McCullough, V.L. Stevens,
A.V. Patel
In this large follow-up study of men diagnosed with nonmetastatic prostate cancer,
engaging in at least 17.5 metabolic equivalent hours or 5 h of moderate-intensity
activity per week may improve prostate cancer–specific survival and overall survival.
940
Why Epidemiological Studies of Physical Activity in Prostate Cancer Often Underestimate its BenefitsM.K. Downer
e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 6 , D e c emb e r 2 0 1 7